ONO-8130
ONO-8130 is an orally active and selective prostanoid EP1 receptor antagonist. ONO-8130 blocks phosphorylation of ERK in the L6 spinal cord. ONO-8130 relieves bladder pain in mice with cyclophosphamide-induced cystitis. ONO-8130 can be used for interstitial cystitis research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 459841-96-4
- Formule: C25H28N2O5S2
- Masse moléculaire:500.63
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
ONO-8130 (30 mg/kg; Orally, once) reverses the established cystitis-related bladder pain[1].
ONO-8130 (30 mg/kg; Orally, once) strongly inhibits phosphorylation of ERK in MDH, DCM, and SPN of the L6 spinal cord caused by intravesical administration of PGE2[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female ddY mice (18-22 g, 4-5 weeks old)[1]
-
Dosage:0.3, 3, 10, and 30 mg/kg
-
Administration:Orally, once
-
Result:Strongly prevented both the bladder pain-like behavior and referred hyperalgesia in a dose-dependent manner, but had slight effect on the increased bladder weight and vascular permeability.
-
Animal Model:Female ddY mice (18-22 g, 4-5 weeks old, established bladder pain caused by IP cyclophosphamide)[1]
-
Dosage:10, 30 mg/kg
-
Administration:Orally, once (administered 2.75 hours after i.p. cyclophosphamide)
-
Result:Markedly attenuated the bladder pain-like nociceptive behavior and referred hyperalgesia in the acute phase (3.5-4 h after cyclophosphamide).
-
Animal Model:Female ddY mice (18-22 g, 4-5 weeks old, established bladder pain caused by IP cyclophosphamide)[1]
-
Dosage:30 mg/kg
-
Administration:Orally, once (administered 4.75 hours after i.p. cyclophosphamide)
-
Result:Significantly suppressed the bladder pain-like nociceptive behavior and tended to reduce the referred hyperalgesia in the persistent phase, 5.5-6 hours after cyclophosphamide.
-
Animal Model:Female ddY mice (18-22 g, 4-5 weeks old, intravesical administration of PGE2 at 5 nmol/mouse)[1]
-
Dosage:30 mg/kg
-
Administration:Orally, once
-
Result:Strongly inhibited phosphorylation of ERK in MDH, DCM, and SPN of the L6 spinal cord caused by intravesical administration of PGE2 at 5 nmol/mouse, exerted complete blockade in DCM, while its inhibitory effects in MDH and SPN were partial.
Chemical Information
-
CAS No. 459841-96-4
-
Masse moléculaire 500.63
-
Formule C25H28N2O5S2
-
SMILES
O=[S](N(C(C=C(CCC1)C1=C2)=C2OCC(C=C3)=CC=C3C(O)=O)CC(C)C)(C4=NC(C)=CS4)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ONO-8130 Related Classifications
HY-110198 Related Classifications
Powered by Bioz